Sensei Biotherapeutics Appoints Deneen Vojta, M.D. to its Board of Directors

BOSTON, MA    and GAITHERSBURG, MD  –  January 29, 2021  – Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointment of Deneen Vojta, M.D. to its Board of Directors. Dr.

Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform

– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON, MA  and ROCKVILLE, MD – January 11, 2021  – Sensei Biotherapeutics, Inc.,

Displaying 11 - 12 of 12